Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort

NCT ID: NCT02228473

Last Updated: 2014-10-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. The adjuncts to reversal agents such as glycopyrrolate and atropine are known to block the muscarinic receptor in different ways.

We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Catheter Site Discomfort Complications Anesthesia Urinary Bladder Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glycopyrrolate

Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.

Group Type EXPERIMENTAL

Glycopyrrolate

Intervention Type DRUG

Glycopyrrolate will be administered.

Atropine

Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.

Group Type ACTIVE_COMPARATOR

Atropine

Intervention Type DRUG

Atropine will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycopyrrolate

Glycopyrrolate will be administered.

Intervention Type DRUG

Atropine

Atropine will be administered.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled for transurethral bladder excision under general anesthesia
* ASA I-III

Exclusion Criteria

* Foley catheter less than 18 Fr.
* Patients with obstruction of urinary tract
* Patients with neurogenic bladder
* Patients with severe obesity
* Patients with neurologic disorder
* Patients with chronic pain
* Patients with allergic history to atropine or glycopyrrolate
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hee-Pyoung Park, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul National University of Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University of Hospital

Seoul, Korea, Republic of, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hyun-Chang Kim, MD

Role: CONTACT

82-10-2886-2876

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hee-Pyoung Park, PhD

Role: primary

+82-10-2971-7647

References

Explore related publications, articles, or registry entries linked to this study.

Kim HC, Lim SM, Seo H, Park HP. Effect of glycopyrrolate versus atropine coadministered with neostigmine for reversal of rocuronium on postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor: a prospective randomized study. J Anesth. 2015 Dec;29(6):831-5. doi: 10.1007/s00540-015-2064-2. Epub 2015 Aug 9.

Reference Type DERIVED
PMID: 26254585 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRBDGlycoAtr

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Laparotomy Study
NCT02140593 COMPLETED PHASE4